atomy bb broad spectrum- titanium dioxide, octinoxate, zinc oxide cream
atomy co., ltd. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37) - titanium dioxide 3.16 g in 40 ml - purpose: sunscreen
atomy mineral compact no.13- titanium dioxide, zinc oxide powder
atomy co., ltd. - titanium dioxide 18.310%, zinc oxide 1.920% - titanium dioxide 2.19 g in 12 g - sunscreen agent
atomy mineral compact no.25- titanium dioxide, zinc oxide powder
atomy co., ltd. - titanium dioxide 18.31%, zinc oxide 1.92% - titanium dioxide 2.19 g in 12 g - sunscreen agent
atomy mineral compact no.23- titanium dioxide, zinc oxide powder
atomy co., ltd. - titanium dioxide 18.31%, zinc oxide 1.92% - titanium dioxide 2.19 g in 12 g - sunscreen agent
atomy mineral compact no.21- titanium dioxide, zinc oxide powder
atomy co., ltd. - titanium dioxide 18.31%, zinc oxide 1.92% - titanium dioxide 2.19 g in 12 g - sunscreen agent
atomy sunscreen white broad spectrum spf50 plus- octinoxate, octisalate, zinc oxide, titanium dioxide cream
atomy co., ltd. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - octinoxate 4.08 mg in 60 ml - purpose: sunscreen
atomy sunscreen beige broad spectrum spf50 plus- octinoxate, octisalate, zinc oxide, titanium dioxide cream
atomy co., ltd. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - octinoxate 4.08 mg in 60 ml - purpose: sunscreen
azor- amlodipine besylate and olmesartan medoxomil tablet, film coated
daiichi sankyo inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with azor. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, ev
azor- amlodipine besylate and olmesartan medoxomil tablet, film coated
physicians total care, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with azor. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, eval
azor- amlodipine besylate and olmesartan medoxomil tablet, film coated
cosette pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with azor. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, ev